Evaluation of controlled hydroxychloroquine releasing performance from calcium-alginate beads

Abstract

The aim of this study was to develop an effective controlled drug delivery system based on alginate beads for the treatment of autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). The present study describes the drug delivery systems to control the effective uses of hydroxychloroquine (HCQ) by Ca-alginate beads. The characterization techniques were employed to evaluate the physicochemical properties as scanning electron microscopy (SEM), swelling test (S), hydrolytic degradation (weight loss, WL) and Fourier transform infrared-attenuated total reflection (FTIR-ATR). The release studies from alginate beads prepared in various drug dose were carried out in the aqueous solutions at different pH (5–8) and temperature (4-37oC). The approximately half-amount of HCQ in HCQ-AB3 was released in 12 h and about 84.38% was released within 8 days. Kinetic model, Korsmeyer-Peppas was applied to model the HCQ release kinetic of alginate beads, which corresponded to non-Fickian transport mechanism.

Keywords

• Calcium-alginate beads
• hydroxychloroquine
• drug delivery
• RA
• SLE

References

1. [1] Kaygusuz H, Erim F. Alginate/BSA/montmorillonite composites with enhanced protein entrapment and controlled release efficiency. Reactive & Functional Polymers 73 (2013) 1420-1425.
2. [2] Kaygusuz H, Torlak E, Akın-Evingür G, Özen İ, Von Klitzing R, Erim FB. Antimicrobial cerium ion-chitosan crosslinked alginate biopolymer films: A novel and potential wound dressing. International Journal of Biological Macromolecules (105) 2017 1161-1165.
3. [3] Tamahkar E, Özkahraman B, Özbaş Z, Izbudak B, Yarimcan F, Boran F, Öztürk AB. Aloe vera-based antibacterial porous sponges for wound dressing applications. Journal of Porous Materials 2021 1-10.
4. [4] Hussain S, Abid MA, Munawar KS, Saddiqa A, Iqbal M, Suleman M, Hussain M, Riaz M, Ahmad T, Abbas A, Rehman m, Amjad M. Choice of Suitable Economic Adsorbents for the Reduction of Heavy Metal Pollution Load. Polish Journal of Environmental Studies 1969-1979.
5. [5] Jayakumar R, Rajkumar M, Freitas H, Selvamurugan N, Nair SV, Furuike T, Tamura H. Preparation, characterization, bioactive and metal uptake studies of alginate/phosphorylated chitin blend films. International Journal of Biological Macromolecules (44) 2009 107-111.
6. [6] Liu C-m, He X-h, Liang R-h, Liu W, Guo WL, Chen J. Relating physicochemical properties of alginate-HMP complexes to their performance as drug delivery systems. Journal of Biomaterials Science, Polymer Edition (28) 2017 2242-2254.
7. [7] Alexander BR, Murphy KE, Gallagher J, Farrell GF, Taggart G. Gelation time, homogeneity, and rupture testing of alginate‐calcium carbonate‐hydrogen peroxide gels for use as wound dressings. Journal of Biomedical Materials Research Part B: Applied Biomaterials (100) 2012 425-431.
8. [8] Liparoti S, Speranza V, Marra F. Alginate hydrogel: The influence of the hardening on the rheological behaviour. Journal of the Mechanical Behavior of Biomedical Materials (116) 2021 104341.

9. [9] Gowri M, Latha N, Suganya K, Murugan M, Rajan M. Calcium alginate nanoparticle crosslinked phosphorylated polyallylamine to the controlled release of clindamycin for osteomyelitis treatment. Drug Development and Industrial Pharmacy (47) 2021 280-291.
10. [10] Lin N, Gèze A, Wouessidjewe D, Huang J, Dufresne A. Biocompatible double-membrane hydrogels from cationic cellulose nanocrystals and anionic alginate as complexing drugs codelivery. ACS Applied Materials & Interfaces (8) 2016 6880-6889.
11. [11] Pongjanyakul T, Rongthong T. Enhanced entrapment efficiency and modulated drug release of alginate beads loaded with drug–clay intercalated complexes as microreservoirs. Carbohydrate Polymers (81) 2010 409-419.
12. [12] Alvarez-Lorenzo C, Concheiro A. 15 Review of Smart Materials for Controlled Drug Release. Fundamentals of Smart Materials 2020 170.
13. [13] Ravi Kumar MN, Kumar § N. Polymeric controlled drug-delivery systems: perspective issues and opportunities. Drug Development and Industrial Pharmacy (27) 2001 1-30.
14. [14] Cunliffe D, Kirby A, Alexander C. Molecularly imprinted drug delivery systems. Advanced Drug Delivery Reviews (57) 2005 1836-1853.
15. [15] Lee E, Kim S, Seong K, Park H, Seo H, Khang G, Lee D. A biodegradable and biocompatible drug-delivery system based on polyoxalate microparticles. Journal of Biomaterials Science, Polymer Edition (22) 2011 1683-1694.
16. [16] da Silva AEA, de Abreu PMB, Geraldes DC, de Oliveira Nascimento L. Hydroxychloroquine: Pharmacological, physicochemical aspects and activity enhancement through experimental formulations. Journal of Drug Delivery Science and Technology (63) 2021 102512.
17. [17] Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld, Y. Hydroxychloroquine: from malaria to autoimmunity. Clinical reviews in allergy & immunology (42) 2012 145-153.
18. [18] Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell (181) 2020 281-292.
19. [19] Rainsford K, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology (23) 2015 231-269.
20. [20] Jamalipour Soufi G, Iravani S. Potential inhibitors of SARS-CoV-2: recent advances. Journal of Drug Targeting 2020 1-16.
21. [21] Tan YW, Yam WK, Sun J, Chu JJH. An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. Antiviral Research (149) 2018 143-149.
22. [22] Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH, Costenbader KH, Ramsey-Goldman R, Lim SS, Esdaile JM, Clarke AE, Urowitz MB, Askanse A, Aranow C, Petri M, Choi H. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. Arthritis Research & Therapy (20) 2018 1-8.
23. [23] McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological Research 2020 104859.
24. [24] Cornet A, Andersen J, Tani C, Mosca M. Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety. Lupus Science & Medicine (8) 2021 e000496.
25. [25] El-Sherbiny IM, Abdel-Mogib M, Dawidar A-AM, Elsayed A, Smyth HD. Biodegradable pH-responsive alginate-poly (lactic-co-glycolic acid) nano/micro hydrogel matrices for oral delivery of silymarin. Carbohydrate Polymers (83) 2011 1345-1354.
26. [26] George M, Abraham T. pH sensitive alginate–guar gum hydrogel for the controlled delivery of protein drugs. International journal of pharmaceutics (335) 2007 123-129.
27. [27] Moraes ANF, Silva LAD, de Oliveira MA, de Oliveira EM, Nascimento TL, Lima E M, Torres LMS, Diniz DGA. Compatibility study of hydroxychloroquine sulfate with pharmaceutical excipients using thermal and nonthermal techniques for the development of hard capsules. Journal of Thermal Analysis and Calorimetry (140) 2020 2283-2292.
28. [28] Çetin K, Alkan H, Bereli N, Denizli A. Molecularly imprinted cryogel as a pH-responsive delivery system for doxorubicin. Journal of Macromolecular Science, Part A (54) 2017 502-508.
29. [29] Prabhakar S, Bajpai J, Bajpai AK, Tiwari A. Cumulative release of cefotaxim from interpenetrating networks of poly (vinyl alcohol-g-acrylamide) and chitosan-g-polyacrylamide chains. Polymer Bulletin (4) 2014 977-988.
30. [30] Shi J, Zhang Z, Li G, Cao S. Biomimetic fabrication of alginate/CaCO 3 hybrid beads for dual-responsive drug delivery under compressed CO 2. Journal of Materials Chemistry (21) 2011 16028-16034.
31. [31] Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. Journal of controlled release (5) 1987 23-36.
32. [32] Sanson C, Schatz C, Le Meins J-F, Soum A, Thévenot J, Garanger E, Lecommandoux S. A simple method to achieve high doxorubicin loading in biodegradable polymersomes. Journal of Controlled Release (147) 2010 428-435.
33. [33] Pasparakis G, Bouropoulos N. Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate–chitosan beads. International journal of pharmaceutics (323) 2006 34-42.
34. [34] Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. Journal of controlled release (5) 1987 5 37-42.
35. [35] Peppas N. Analysis of Fickian and non-Fickian drug release from polymers. Pharmaceutica Acta Helvetiae (60) 1985 110-111.